AnaptysBio Price Target Raised To $145 From $101 At Jefferies
February 19, 2018 at 14:20 PM EST
Jefferies analyst Biren Amin raised his price target for AnaptysBio to $145 after the company presented final data from its Phase IIa trial of ANB020 in 12 mod-to-severe adult atopic dermatitis patients.
